Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Malignant Melanoma

  Free Subscription


Articles published in J Invest Dermatol

Retrieve available abstracts of 149 articles:
HTML format
Text format



Single Articles


    August 2018
  1. PAMPENA R, Pellacani G, Longo C
    Nevus-Associated Melanoma: Patient Phenotype and Potential Biological Implications.
    J Invest Dermatol. 2018;138:1696-1698.
    PubMed     Text format     Abstract available


  2. SAHOO A, Sahoo SK, Joshi P, Lee B, et al
    MicroRNA-211 loss promotes metabolic vulnerability and BRAF inhibitor sensitivity in melanoma.
    J Invest Dermatol. 2018 Aug 1. pii: S0022-202X(18)32458.
    PubMed     Text format     Abstract available


    July 2018
  3. RAMSPOTT JP, Bekkat F, Bod L, Favier M, et al
    Emerging role of IL4-induced gene 1 as a prognostic biomarker affecting the local T cell response in human cutaneous melanoma.
    J Invest Dermatol. 2018 Jul 23. pii: S0022-202X(18)32301.
    PubMed     Text format     Abstract available


  4. NOSRATI A, Yu WY, McGuire J, Griffin A, et al
    Outcomes and risk factors in patients with multiple primary melanomas.
    J Invest Dermatol. 2018 Jul 19. pii: S0022-202X(18)32359.
    PubMed     Text format     Abstract available


  5. FORSTHUBER A, Lipp K, Andersen L, Ebersberger S, et al
    CXCL5 as regulator of neutrophil function in cutaneous melanoma.
    J Invest Dermatol. 2018 Jul 13. pii: S0022-202X(18)32353.
    PubMed     Text format     Abstract available


  6. TAKAISHI M, Sano S
    Transdifferentiation of melanoma cells by the reprogramming factors attenuates malignant nature in vitro and in vivo.
    J Invest Dermatol. 2018 Jul 7. pii: S0022-202X(18)32303.
    PubMed     Text format    


    June 2018
  7. CUST AE, Drummond M, Kanetsky PA, Goldstein AM, et al
    Assessing the incremental contribution of common genomic variants to melanoma risk prediction in two population-based studies.
    J Invest Dermatol. 2018 Jun 8. pii: S0022-202X(18)32046.
    PubMed     Text format     Abstract available


    May 2018
  8. RAMANI V, Teshima T, Tamura K, Chung JS, et al
    Melanoma-derived Soluble DC-HIL/GPNMB Promotes Metastasis by Excluding T-lymphocytes from the Pre-metastatic Niches.
    J Invest Dermatol. 2018 May 29. pii: S0022-202X(18)31987.
    PubMed     Text format     Abstract available


  9. NAWAZ A, Wong TW
    Chitosan-carboxymethyl-5-fluorouracil-folate conjugate particles: Microwave modulated uptake by skin and melanoma cells.
    J Invest Dermatol. 2018 May 29. pii: S0022-202X(18)31985.
    PubMed     Text format     Abstract available


  10. THOMAS NE, Edmiston SN, Orlow I, Kanetsky PA, et al
    Inherited Genetic Variants Associated with Melanoma BRAF/NRAS Subtypes.
    J Invest Dermatol. 2018 May 9. pii: S0022-202X(18)31962.
    PubMed     Text format     Abstract available


  11. OLSEN CM, Pandeya N, Thompson BS, Dusingize JC, et al
    Physician skin checks before the diagnosis of melanoma correlate with tumor characteristics.
    J Invest Dermatol. 2018 May 4. pii: S0022-202X(18)31952.
    PubMed     Text format    


    April 2018
  12. NORDLINGER A, Dror S, Elkahloun A, Del Rio J, et al
    Mutated MITF-E87R in Melanoma Enhances Tumor Progression via S100A4.
    J Invest Dermatol. 2018 Apr 18. pii: S0022-202X(18)31873.
    PubMed     Text format     Abstract available


    March 2018
  13. YANG Y, Guo W, Ma J, Xu P, et al
    Down-regulated TRPV1 expression contributes to melanoma growth via calcineurin-ATF3-p53 pathway.
    J Invest Dermatol. 2018 Mar 23. pii: S0022-202X(18)31748.
    PubMed     Text format     Abstract available


  14. PANDEYA N, Kvaskoff M, Olsen CM, Green AC, et al
    Factors related to nevus-associated cutaneous melanoma: a case-case study.
    J Invest Dermatol. 2018 Mar 7. pii: S0022-202X(18)30204.
    PubMed     Text format     Abstract available


    February 2018
  15. SOLER-CARDONA A, Forsthuber A, Lipp K, Ebersberger S, et al
    CXCL5 facilitates melanoma cell-neutrophil interaction and lymph node metastasis.
    J Invest Dermatol. 2018 Feb 20. pii: S0022-202X(18)30125.
    PubMed     Text format     Abstract available


  16. LIN J, Zhang D, Fan Y, Chao Y, et al
    Regulation of cancer stem cell self-renewal by HOXB9 antagonizes ER stress-induced melanoma cell apoptosis via the miR-765-FOXA2 axis.
    J Invest Dermatol. 2018 Feb 3. pii: S0022-202X(18)30105.
    PubMed     Text format     Abstract available


  17. TUCKER MA, Elder DE, Curry M, Fraser MC, et al
    Risks of melanoma and other cancers in melanoma-prone families over four decades.
    J Invest Dermatol. 2018 Feb 2. pii: S0022-202X(18)30102.
    PubMed     Text format     Abstract available


  18. ELIADES P, Abraham BJ, Ji Z, Miller DM, et al
    High MITF Expression is Associated with Super-enhancers and Suppressed by CDK7 Inhibition in Melanoma.
    J Invest Dermatol. 2018 Feb 2. pii: S0022-202X(18)30106.
    PubMed     Text format     Abstract available


  19. CARRERA C, Puig-Butille JA
    Clinical, Epidemiological, and Molecular Heterogeneity in Acral Melanoma.
    J Invest Dermatol. 2018;138:254-255.
    PubMed     Text format     Abstract available


    January 2018
  20. FAIAO-FLORES F, Smalley KSM
    Get with the Program! Stemness and Reprogramming in Melanoma Metastasis.
    J Invest Dermatol. 2018;138:10-13.
    PubMed     Text format     Abstract available


    December 2017
  21. OGAWA H, Luxardi G, Kirane A, Kulkarni R, et al
    T cells dominate the local immune response induced by intralesional IL-2 in combination with imiquimod and retinoid for in-transit metastatic melanoma.
    J Invest Dermatol. 2017 Dec 29. pii: S0022-202X(17)33369.
    PubMed     Text format    


  22. CONIC RZ, Arbesman J
    Melanoma Tumor Characteristics: An Analysis of Mutational Burden and Copy Number Alterations by Patient Age and Stage.
    J Invest Dermatol. 2017 Dec 5. pii: S0022-202X(17)33236.
    PubMed     Text format    


  23. KASUMOVA GG, Haynes AB, Boland GM
    Lymphatic versus Hematogenous Melanoma Metastases: Support for Biological Heterogeneity without Clear Clinical Application.
    J Invest Dermatol. 2017;137:2466-2468.
    PubMed     Text format     Abstract available


  24. CHHABRA G, Wojdyla L, Frakes M, Schrank Z, et al
    Mechanism of action of G-quadruplex forming oligonucleotide homologous to the telomere overhang in melanoma.
    J Invest Dermatol. 2017 Dec 1. pii: S0022-202X(17)33229.
    PubMed     Text format     Abstract available


    November 2017
  25. MOON KR, Choi YD, Kim JM, Jin S, et al
    Genetic Alterations in Primary Acral Melanoma and Acral Melanocytic Nevus in Korea: Common Mutated Genes Show Distinct Cytomorphological Features.
    J Invest Dermatol. 2017 Nov 27. pii: S0022-202X(17)33225.
    PubMed     Text format     Abstract available


  26. LIU SM, Lin CH, Lu J, Lin IY, et al
    miR-596 modulates melanoma growth by regulating cell survival and death.
    J Invest Dermatol. 2017 Nov 25. pii: S0022-202X(17)33172.
    PubMed     Text format     Abstract available


  27. WANG YF, Liu F, Sherwin S, Farrelly M, et al
    Cooperativity of HOXA5 and STAT3 is critical for HDAC8 inhibition-mediated transcriptional activation of PD-L1 in human melanoma cells.
    J Invest Dermatol. 2017 Nov 22. pii: S0022-202X(17)33164.
    PubMed     Text format     Abstract available


  28. LOHCHAROENKAL W, Das Mahapatra K, Pasquali L, Crudden C, et al
    Genome-wide screen for microRNAs reveals a role for miR-203 in melanoma metastasis.
    J Invest Dermatol. 2017 Nov 2. pii: S0022-202X(17)33137.
    PubMed     Text format     Abstract available


    October 2017
  29. RUBEL F, Kern JS, Technau-Hafsi K, Uhrich S, et al
    Indoleamine 2,3-dioxygenase expression in primary cutaneous melanoma correlates with Breslow thickness and is of significant prognostic value for progression-free survival.
    J Invest Dermatol. 2017 Oct 17. pii: S0022-202X(17)33059.
    PubMed     Text format     Abstract available


    September 2017
  30. HEPPT MV, Wang JX, Hristova DM, Wei Z, et al
    MSX1-induced neural crest-like reprogramming promotes melanoma progression.
    J Invest Dermatol. 2017 Sep 16. pii: S0022-202X(17)32807.
    PubMed     Text format     Abstract available


  31. HAO J, Xu H, Luo M, Yu W, et al
    The tumor-promoting role of TRIP4 in melanoma progression and its involvement in response to BRAF-targeted therapy.
    J Invest Dermatol. 2017 Sep 9. pii: S0022-202X(17)32937.
    PubMed     Text format     Abstract available


  32. YU B, Alboslemy T, Safadi F, Kim MH, et al
    Glycoprotein non-melanoma clone B regulates the crosstalk between macrophages and mesenchymal stem cells towards wound repair.
    J Invest Dermatol. 2017 Sep 9. pii: S0022-202X(17)32934.
    PubMed     Text format     Abstract available


  33. HAUGH AM, Zhang B, Quan VL, Garfield EM, et al
    Distinct Patterns of Acral Melanoma Based on Site and Relative Sun Exposure.
    J Invest Dermatol. 2017 Sep 1. pii: S0022-202X(17)32917.
    PubMed     Text format     Abstract available


    August 2017
  34. DONOVAN P, Dubey OA, Kallioinen S, Rogers KW, et al
    Paracrine Activin-A signaling promotes melanoma growth and metastasis through immune evasion.
    J Invest Dermatol. 2017 Aug 24. pii: S0022-202X(17)32820.
    PubMed     Text format     Abstract available


  35. DELYON J, Chevret S, Jouary T, Dalac S, et al
    STAT3 mediates Nilotinib response in KIT-altered Melanoma: a Phase II Multicenter Trial of the French Skin Cancer Network.
    J Invest Dermatol. 2017 Aug 23. pii: S0022-202X(17)32802.
    PubMed     Text format     Abstract available


  36. THOMAS NE, Edmiston SN, Kanetsky PA, Busam KJ, et al
    Associations of MC1R genotype and patient phenotypes with BRAF and NRAS mutations in melanoma.
    J Invest Dermatol. 2017 Aug 22. pii: S0022-202X(17)32791.
    PubMed     Text format     Abstract available


  37. VON SCHUCKMANN LA, Smith D, Hughes MCB, Malt M, et al
    Associations of statins and diabetes with diagnosis of ulcerated cutaneous melanoma.
    J Invest Dermatol. 2017 Aug 22. pii: S0022-202X(17)32797.
    PubMed     Text format     Abstract available


  38. TAYLOR NJ, Mitra N, Goldstein AM, Tucker MA, et al
    Germline variation at CDKN2A and associations with nevus phenotypes among members of melanoma families.
    J Invest Dermatol. 2017 Aug 19. pii: S0022-202X(17)32759.
    PubMed     Text format     Abstract available


    July 2017
  39. DAI W, Xu X, Li S, Ma J, et al
    SOX4 promotes proliferative signals by regulating glycolysis through AKT activation in melanoma cells.
    J Invest Dermatol. 2017 Jul 28. pii: S0022-202X(17)32684.
    PubMed     Text format     Abstract available


  40. ISHIDA Y, Otsuka A, Tanaka H, Levesque MP, et al
    HLA-A*26 is correlated with response to nivolumab in Japanese melanoma patients.
    J Invest Dermatol. 2017 Jul 20. pii: S0022-202X(17)31863.
    PubMed     Text format    


  41. CLARKE CA, McKinley M, Hurley S, Haile RW, et al
    Continued increase in melanoma incidence across all socioeconomic status groups in California, 1998-2012.
    J Invest Dermatol. 2017 Jul 20. pii: S0022-202X(17)31867.
    PubMed     Text format     Abstract available


  42. GASSENMAIER M, Eigentler TK, Keim U, Goebeler M, et al
    Serial or Parallel Metastasis of Cutaneous Melanoma? A Study of the German Central Malignant Melanoma Registry.
    J Invest Dermatol. 2017 Jul 20. pii: S0022-202X(17)31871.
    PubMed     Text format     Abstract available


    June 2017
  43. VAN TUYN J, Jaber-Hijazi F, MacKenzie D, Cole JJ, et al
    Oncogene-Expressing Senescent Melanocytes Upregulate Mhc Class Ii, A Candidate Melanoma Suppressor Function.
    J Invest Dermatol. 2017 Jun 21. pii: S0022-202X(17)31662.
    PubMed     Text format     Abstract available


  44. ASGARI MM, Chien AJ, Tsai AL, Fireman B, et al
    Association between lithium use and melanoma risk and mortality: A population-based study.
    J Invest Dermatol. 2017 Jun 16. pii: S0022-202X(17)31644.
    PubMed     Text format     Abstract available


  45. THEODOSAKIS N, Micevic G, Langdon CG, Ventura A, et al
    p90RSK blockade inhibits dual BRAF and MEK inhibitor-resistant melanoma by targeting protein synthesis.
    J Invest Dermatol. 2017 Jun 6. pii: S0022-202X(17)31603.
    PubMed     Text format     Abstract available


    May 2017
  46. BUSTOS MA, Ono S, Marzese DM, Oyama T, et al
    MiR-200a Regulates CDK4/6 Inhibitor Effect by targeting CDK6 in Metastatic Melanoma.
    J Invest Dermatol. 2017 May 16. pii: S0022-202X(17)31528.
    PubMed     Text format     Abstract available


  47. SHI Q, Liu H, Han P, Li C, et al
    Genetic Variants in WNT2B and BTRC Predict Melanoma Survival.
    J Invest Dermatol. 2017 May 9. pii: S0022-202X(17)31489.
    PubMed     Text format     Abstract available


  48. LEITER U, Keim U, Eigentler T, Katalinic A, et al
    Incidence, Mortality and Trends of Non-Melanoma Skin Cancer in Germany.
    J Invest Dermatol. 2017 May 6. pii: S0022-202X(17)31482.
    PubMed     Text format     Abstract available


  49. BAUER J
    The Molecular Revolution in Cutaneous Biology: Era of Cytogenetics and Copy Number Analysis.
    J Invest Dermatol. 2017;137:e57-e59.
    PubMed     Text format     Abstract available


    April 2017
  50. FANG S, Wang Y, Dang Y, Gagel A, et al
    Association between body mass index, C-reactive protein levels, and melanoma patient outcomes.
    J Invest Dermatol. 2017 Apr 22. pii: S0022-202X(17)31423.
    PubMed     Text format    


  51. KIM SH, Li M, Trousil S, Zhang Y, et al
    Phenformin inhibits myeloid-derived suppressor cells and enhances the anti-tumor activity of PD-1 blockade in melanoma.
    J Invest Dermatol. 2017 Apr 19. pii: S0022-202X(17)31420.
    PubMed     Text format     Abstract available


  52. SEO EY, Jin SP, Sohn KC, Park CH, et al
    UCHL1 Regulates Melanogenesis through Controlling MITF Stability in Human Melanocytes.
    J Invest Dermatol. 2017 Apr 6. pii: S0022-202X(17)31396.
    PubMed     Text format     Abstract available


  53. SFECCI A, Dupuy A, Dinulescu M, Droitcourt C, et al
    Do the Side Effects of BRAF Inhibitors Mimic RASopathies?
    J Invest Dermatol. 2017;137:805-809.
    PubMed     Text format     Abstract available


    February 2017
  54. PUIG-BUTILLE JA, Vinyals A, Ferreres JR, Aguilera P, et al
    AURORA A overexpression (AURKA) is driven by FOXM1 and MAPK/ERK activation in melanoma cells harbouring BRAF or NRAS mutations: Impact on melanoma prognosis and therapy.
    J Invest Dermatol. 2017 Feb 7. pii: S0022-202X(17)30115.
    PubMed     Text format     Abstract available


  55. ZHOU Y, Tripathi SV, Rosman I, Ma J, et al
    Noninvasive Determination of Melanoma Depth using a Handheld Photoacoustic Probe.
    J Invest Dermatol. 2017 Feb 2. pii: S0022-202X(17)30104.
    PubMed     Text format    


    January 2017
  56. TROUSIL S, Chen S, Mu C, Shaw FM, et al
    Phenformin enhances the efficacy of ERK inhibition in NF1-mutant melanoma.
    J Invest Dermatol. 2017 Jan 28. pii: S0022-202X(17)30052.
    PubMed     Text format     Abstract available


  57. TSAO H, Fukunaga-Kalabis M, Herlyn M
    Recent Advances in Melanoma and Melanocyte Biology.
    J Invest Dermatol. 2017 Jan 12. pii: S0022-202X(16)32640.
    PubMed     Text format    


    December 2016
  58. ROOS L, Sandling JK, Bell CG, Glass D, et al
    Higher Naevus Count Exhibits A Distinct DNA Methylation Signature in Healthy Human Skin: Implications for Melanoma.
    J Invest Dermatol. 2016 Dec 16. pii: S0022-202X(16)32787.
    PubMed     Text format     Abstract available


  59. KAWAKAMI A, Fisher DE
    Bioinformatic Analysis of Gene Expression for Melanoma Treatment.
    J Invest Dermatol. 2016;136:2342-2344.
    PubMed     Text format     Abstract available


    November 2016
  60. MELAMED RD, Aydin IT, Rajan GS, Phelps R, et al
    Genomic Characterization of Dysplastic Nevi Unveils Implications for Diagnosis of Melanoma.
    J Invest Dermatol. 2016 Nov 24. pii: S0022-202X(16)32663.
    PubMed     Text format     Abstract available


  61. CHIANG NY, Peng YM, Juang HH, Chen TC, et al
    GPR56/ADGRG1 activation promotes melanoma cell migration via NTF dissociation and CTF-mediated Galpha12/13/RhoA signaling.
    J Invest Dermatol. 2016 Nov 3. pii: S0022-202X(16)32618.
    PubMed     Text format     Abstract available


    October 2016
  62. KOHLI JS, Tolomio E, Frigerio S, Maurichi A, et al
    Common Delayed Senescence of Melanocytes from Multiple Primary Melanoma Patients.
    J Invest Dermatol. 2016 Oct 28. pii: S0022-202X(16)32610.
    PubMed     Text format    


  63. ELIADES P, Tsao H
    New Insights into the Molecular Distinction of Dysplastic Nevi and Common Melanocytic Nevi-Highlighting the Keratinocyte-Melanocyte Relationship.
    J Invest Dermatol. 2016;136:1933-5.
    PubMed     Text format     Abstract available


    September 2016
  64. VIARISIO D, Muller-Decker K, Hassel JC, Alvarez JC, et al
    The BRAF inhibitor vemurafenib enhances UV-induced skin carcinogenesis in beta HPV38 E6 and E7 transgenic mice.
    J Invest Dermatol. 2016 Sep 17. pii: S0022-202X(16)32449.
    PubMed     Text format    


  65. LUCARINI V, Buccione C, Ziccheddu G, Peschiaroli F, et al
    Combining Type I Interferons and 5-Aza-2'-Deoxycitidine to improve anti-tumor response against melanoma.
    J Invest Dermatol. 2016 Sep 10. pii: S0022-202X(16)32368.
    PubMed     Text format     Abstract available


  66. RUNGER TM
    Mechanisms of Melanoma Promotion by Ultraviolet Radiation.
    J Invest Dermatol. 2016;136:1751-2.
    PubMed     Text format     Abstract available


    August 2016
  67. FANG S, Vaysse A, Brossard M, Wang Y, et al
    Melanoma expression genes identified through genome-wide association study of Breslow tumor thickness.
    J Invest Dermatol. 2016 Aug 6. pii: S0022-202X(16)32250.
    PubMed     Text format    


  68. MATHEIS F, Heppt MV, Graf SA, Duwell P, et al
    A bifunctional approach of immunostimulation and uPAR inhibition shows potent antitumor activity in melanoma.
    J Invest Dermatol. 2016 Aug 3. pii: S0022-202X(16)32234.
    PubMed     Text format     Abstract available


    July 2016
  69. SHI J, Zhou W, Zhu B, Hyland PL, et al
    Rare germline copy number variations and disease susceptibility in familial melanoma.
    J Invest Dermatol. 2016 Jul 28. pii: S0022-202X(16)32229.
    PubMed     Text format     Abstract available


  70. KUMAR D, Kumar S, Gorain M, Tomar D, et al
    Notch1-MAPK Signaling Axis Regulates CD133+ Cancer Stem Cell-Mediated Melanoma Growth and Angiogenesis.
    J Invest Dermatol. 2016 Jul 28. pii: S0022-202X(16)32232.
    PubMed     Text format     Abstract available


  71. PAVLOVA O, Fraitag S, Hohl D
    5-hydroxymethylcytosine expression in proliferative nodules arising within congenital nevi allows differentiation from malignant melanoma.
    J Invest Dermatol. 2016 Jul 22. pii: S0022-202X(16)32124.
    PubMed     Text format     Abstract available


  72. WEIDE B, Schafer T, Martens A, Kuzkina A, et al
    High GDF-15 serum levels independently correlate with poorer overall survival of tumor-free stage III and unresectable stage IV melanoma patients.
    J Invest Dermatol. 2016 Jul 22. pii: S0022-202X(16)32125.
    PubMed     Text format     Abstract available


  73. WANG JY, Jin L, Yan XG, Sherwin S, et al
    Reactive oxygen species dictate the apoptotic response of melanoma cells to TH588.
    J Invest Dermatol. 2016 Jul 14. pii: S0022-202X(16)32104.
    PubMed     Text format     Abstract available


  74. GULATI N, Garcet S, Fuentes-Duculan J, Gilleaudeau P, et al
    Molecular profiling of immune activation associated with regression of melanoma metastases induced by diphencyprone.
    J Invest Dermatol. 2016 Jul 1. pii: S0022-202X(16)32084.
    PubMed     Text format    


    June 2016
  75. PIETROBONO S, Morandi A, Gagliardi S, Gerlini G, et al
    Downregulation of SOX2 underlies the inhibitory effects of the triphenylmethane gentian violet on melanoma cell self-renewal and survival.
    J Invest Dermatol. 2016 Jun 29. pii: S0022-202X(16)32083.
    PubMed     Text format     Abstract available


  76. GIMOTTY PA, Shore R, Lozon N, Whitlock J, et al
    Miscoding of melanoma thickness in SEER: Research and clinical implications.
    J Invest Dermatol. 2016 Jun 25. pii: S0022-202X(16)31960.
    PubMed     Text format    


  77. GREVELING K, Wakkee M, Nijsten T, van den Bos RR, et al
    Epidemiology of lentigo maligna and lentigo maligna melanoma in the Netherlands, 1989 - 2013.
    J Invest Dermatol. 2016 Jun 24. pii: S0022-202X(16)31365.
    PubMed     Text format     Abstract available


  78. LAUSS M, Nsengimana J, Staaf J, Newton-Bishop J, et al
    Consensus of melanoma gene expression subtypes converges on biological entities.
    J Invest Dermatol. 2016 Jun 23. pii: S0022-202X(16)31363.
    PubMed     Text format    


  79. SALTARI A, Truzzi F, Quadri M, Lotti R, et al
    CD271 downregulation promotes melanoma progression and invasion in 3-dimensional models and in zebrafish.
    J Invest Dermatol. 2016 Jun 17. pii: S0022-202X(16)31351.
    PubMed     Text format     Abstract available


  80. CASULA M, Colombino M, Manca A, Caraco C, et al
    Low levels of genetic heterogeneity in matched lymph node metastases from melanoma patients.
    J Invest Dermatol. 2016 Jun 2. pii: S0022-202X(16)31332.
    PubMed     Text format    


    May 2016
  81. NAJITA JS, Swetter SM, Geller AC, Gershenwald JE, et al
    Sex differences in age at primary melanoma diagnosis in a population-based analysis (US Surveillance, Epidemiology, and End Results, 2005-2011).
    J Invest Dermatol. 2016 May 29. pii: S0022-202X(16)31263.
    PubMed     Text format    


  82. POSCH C, Sanlorenzo M, Vujic I, Oses-Prieto JA, et al
    Phospho-proteomic analyses of NRAS(G12) and NRAS(Q61) mutant melanocytes reveal increased CK2alpha kinase levels in NRAS(Q61) mutant cells.
    J Invest Dermatol. 2016 May 29. pii: S0022-202X(16)31261.
    PubMed     Text format     Abstract available


  83. WHITEMAN DC, Green AC, Olsen CM
    The relentless rise in the incidence of melanoma in susceptible Australians - Response.
    J Invest Dermatol. 2016 May 25. pii: S0022-202X(16)31259.
    PubMed     Text format    


  84. HALABAN R, Krauthammer M
    RASopathy Gene Mutations in Melanoma.
    J Invest Dermatol. 2016 May 25. pii: S0022-202X(16)31257.
    PubMed     Text format     Abstract available


  85. CZARNECKI D
    The relentless rise in the incidence of melanoma in susceptible Australians.
    J Invest Dermatol. 2016 May 25. pii: S0022-202X(16)31151.
    PubMed     Text format    


  86. YELAMOS O, Merkel EA, Sholl LM, Zhang B, et al
    Non-overlapping Clinical and Mutational Patterns in Melanomas from the Female Genital Tract and Atypical Genital Nevi.
    J Invest Dermatol. 2016 May 21. pii: S0022-202X(16)31256.
    PubMed     Text format     Abstract available


  87. KAMENISCH Y, Baban TS, Schuller W, von Thaler AK, et al
    UVA-irradiation induces melanoma invasion via enhanced Warburg effect.
    J Invest Dermatol. 2016 May 13. pii: S0022-202X(16)31243.
    PubMed     Text format     Abstract available


  88. POSCH C, Vujic I, Monshi B, Sanlorenzo M, et al
    Searching for the Chokehold of NRAS Mutant Melanoma.
    J Invest Dermatol. 2016 May 7. pii: S0022-202X(16)30881.
    PubMed     Text format     Abstract available


    April 2016
  89. VAN DE NES J, Wrede K, Ringelstein A, Stiller M, et al
    Diagnosing a primary leptomeningeal melanoma by gene mutation signature.
    J Invest Dermatol. 2016 Apr 6. pii: S0022-202X(16)31023.
    PubMed     Text format    


    March 2016
  90. YOULDEN DR, Baade PD, Soyer HP, Youl PH, et al
    Ten-year survival after multiple invasive melanomas is worse than after a single melanoma: a population-based study.
    J Invest Dermatol. 2016 Mar 23. pii: S0022-202X(16)30930.
    PubMed     Text format     Abstract available


  91. BEAUMONT KA, Hill DS, Daignault SM, Lui GY, et al
    Cell cycle phase-specific drug resistance as an escape mechanism of melanoma cells.
    J Invest Dermatol. 2016 Mar 9. pii: S0022-202X(16)30862.
    PubMed     Text format     Abstract available


  92. RAMBOW F, Bechadergue A, Luciani F, Gros G, et al
    Regulation of melanoma progression through the TCF4/miR-125b/NEDD9 cascade.
    J Invest Dermatol. 2016 Mar 8. pii: S0022-202X(16)30857.
    PubMed     Text format     Abstract available


  93. KYPREOU KP, Stefanaki I, Antonopoulou K, Karagianni F, et al
    Prediction of Melanoma Risk in a Southern European Population Based on a Weighted Genetic Risk Score.
    J Invest Dermatol. 2016;136:690-695.
    PubMed     Text format     Abstract available


    February 2016
  94. WHITEMAN DC, Green AC, Olsen CM
    The growing burden of invasive melanoma: projections of incidence rates and numbers of new cases in six susceptible populations to 2031.
    J Invest Dermatol. 2016 Feb 19. pii: S0022-202X(16)00488.
    PubMed     Text format     Abstract available


  95. GE R, Liu L, Dai W, Zhang W, et al
    XPA promotes autophagy to facilitate cisplatin resistance in melanoma cells through the activation of PARP1.
    J Invest Dermatol. 2016 Feb 12. pii: S0022-202X(16)00468.
    PubMed     Text format     Abstract available


  96. ROH MR, Gupta S, Park KH, Chung KY, et al
    Promoter Methylation of PTEN is a Significant Prognostic Factor in Melanoma Survival.
    J Invest Dermatol. 2016 Feb 5. pii: S0022-202X(16)00458.
    PubMed     Text format     Abstract available


  97. LANDSBERG J, Tuting T, Barnhill RL, Lugassy C, et al
    The Role of Neutrophilic Inflammation, Angiotropism, and Pericytic Mimicry in Melanoma Progression and Metastasis.
    J Invest Dermatol. 2016;136:372-7.
    PubMed     Text format     Abstract available


  98. SZEGEZDI E, Leverkus M
    Guiding the Killer and Bringing in Accomplices: Bispecific Antibody Treatment for Malignant Melanoma.
    J Invest Dermatol. 2016;136:362-4.
    PubMed     Text format     Abstract available


  99. HE Y, Hendriks D, van Ginkel R, Samplonius D, et al
    Melanoma-Directed Activation of Apoptosis Using a Bispecific Antibody Directed at MCSP and TRAIL Receptor-2/Death Receptor-5.
    J Invest Dermatol. 2016;136:541-544.
    PubMed     Text format    


  100. ZHANG K, Wong P, Salvaggio C, Salhi A, et al
    Synchronized Targeting of Notch and ERBB Signaling Suppresses Melanoma Tumor Growth through Inhibition of Notch1 and ERBB3.
    J Invest Dermatol. 2016;136:464-472.
    PubMed     Text format     Abstract available


  101. VU HL, Rosenbaum S, Capparelli C, Purwin TJ, et al
    MIG6 Is MEK Regulated and Affects EGF-Induced Migration in Mutant NRAS Melanoma.
    J Invest Dermatol. 2016;136:453-463.
    PubMed     Text format     Abstract available


    January 2016
  102. GUO S, Guo W, Li S, Dai W, et al
    Serum miR-16: a potential biomarker for predicting melanoma prognosis.
    J Invest Dermatol. 2016 Jan 29. pii: S0022-202X(16)00365.
    PubMed     Text format    


  103. PUUJALKA E, Heinz M, Hoesel B, Friedl P, et al
    Opposing roles of JNK and p38 in lymphangiogenesis in melanoma.
    J Invest Dermatol. 2016 Jan 29. pii: S0022-202X(16)00374.
    PubMed     Text format     Abstract available


  104. JACQUELOT N, Roberti MP, Enot DP, Rusakiewicz S, et al
    Immunophenotyping of stage III melanoma reveals parameters associated with patient prognosis.
    J Invest Dermatol. 2016 Jan 29. pii: S0022-202X(16)00366.
    PubMed     Text format     Abstract available


  105. TAYLOR NJ, Handorf EA, Mitra N, Avril MF, et al
    Phenotypic and histopathological tumor characteristics according to CDKN2A mutation status among affected members of melanoma families.
    J Invest Dermatol. 2016 Jan 28. pii: S0022-202X(16)00355.
    PubMed     Text format    


  106. HACKER E, Olsen CM, Kvaskoff M, Pandeya N, et al
    Histologic and phenotypic factors and MC1R status associated with BRAF, BRAF and NRAS mutations in a community-based sample of 414 cutaneous melanomas.
    J Invest Dermatol. 2016 Jan 22. pii: S0022-202X(16)00351.
    PubMed     Text format     Abstract available


  107. FAN Y, Lee S, Wu G, Easton J, et al
    Telomerase Expression by Aberrant Methylation of the TERT Promoter in Melanoma Arising in Giant Congenital Nevi.
    J Invest Dermatol. 2016;136:339-42.
    PubMed     Text format    


  108. UGUEN A, Talagas M, Marcorelles P, De Braekeleer M, et al
    BRAFV600E and NRASQ61R Homogeneity in Melanoma Tumors.
    J Invest Dermatol. 2016;136:337-8.
    PubMed     Text format    


  109. PATHRIA G, Garg B, Wagner C, Garg K, et al
    RanBP3 Regulates Melanoma Cell Proliferation via Selective Control of Nuclear Export.
    J Invest Dermatol. 2016;136:264-74.
    PubMed     Text format     Abstract available


  110. INOZUME T, Yaguchi T, Furuta J, Harada K, et al
    Melanoma Cells Control Antimelanoma CTL Responses via Interaction between TIGIT and CD155 in the Effector Phase.
    J Invest Dermatol. 2016;136:255-63.
    PubMed     Text format     Abstract available


  111. JAYAWARDANA K, Schramm SJ, Tembe V, Mueller S, et al
    Identification, Review, and Systematic Cross-Validation of microRNA Prognostic Signatures in Metastatic Melanoma.
    J Invest Dermatol. 2016;136:245-54.
    PubMed     Text format     Abstract available


  112. NAKAHARA T, Oba J, Shimomura C, Kido-Nakahara M, et al
    Early Tumor-Infiltrating Dendritic Cells Change their Characteristics Drastically in Association with Murine Melanoma Progression.
    J Invest Dermatol. 2016;136:146-53.
    PubMed     Text format     Abstract available


  113. MAHNKE K, Enk AH
    TIGIT-CD155 Interactions in Melanoma: A Novel Co-Inhibitory Pathway with Potential for Clinical Intervention.
    J Invest Dermatol. 2016;136:9-11.
    PubMed     Text format     Abstract available


    December 2015
  114. BUZAS K, Marton A, Vizler C, Gyukity-Sebestyen E, et al
    Bacterial sepsis increases survival in metastatic melanoma: Chlamydophila pneumoniae induces macrophage polarization and tumor regression.
    J Invest Dermatol. 2015 Dec 29. pii: S0022-202X(15)00328.
    PubMed     Text format    


  115. GEORGE J, Nihal M, Singh CK, Zhong W, et al
    Pro-proliferative function of mitochondrial sirtuin deacetylase SIRT3 in human melanoma.
    J Invest Dermatol. 2015 Dec 29. pii: S0022-202X(15)00322.
    PubMed     Text format     Abstract available


  116. CHANG GA, Polsky D
    Mutational Heterogeneity in Melanoma: An Inconvenient Truth.
    J Invest Dermatol. 2015;135:2913-8.
    PubMed     Text format     Abstract available


  117. FEDORENKO IV, Wargo JA, Flaherty KT, Messina JL, et al
    BRAF Inhibition Generates a Host-Tumor Niche that Mediates Therapeutic Escape.
    J Invest Dermatol. 2015;135:3115-24.
    PubMed     Text format     Abstract available


  118. MENON DR, Schaider H
    Microenvironment-Driven Resistance to BRAF Inhibition Comes of Age.
    J Invest Dermatol. 2015;135:2923-5.
    PubMed     Text format     Abstract available


    November 2015
  119. WHITEMAN DC, Olsen CM
    Melanoma Incidence and Lethality Is Increased Following Solid Organ Transplantation.
    J Invest Dermatol. 2015;135:2560-2.
    PubMed     Text format     Abstract available


    October 2015
  120. INOZUME T, Yaguchi T, Furuta J, Harada K, et al
    Melanoma Cells Control Anti-Melanoma CTL Responses via Interaction between TIGIT and CD155 in the Effector Phase.
    J Invest Dermatol. 2015 Oct 12. doi: 10.1038/jid.2015.
    PubMed     Text format     Abstract available


  121. PATHRIA G, Garg B, Wagner C, Garg K, et al
    RanBP3 Regulates Melanoma Cell Proliferation via Selective Control of Nuclear Export.
    J Invest Dermatol. 2015 Oct 8. doi: 10.1038/jid.2015.
    PubMed     Text format     Abstract available


  122. CHEN HY, Villanueva J
    Playing Polo-Like Kinase in NRAS-Mutant Melanoma.
    J Invest Dermatol. 2015;135:2352-5.
    PubMed     Text format     Abstract available


  123. ALDAHAN AS, Mlacker S, Shah VV, Samarkandy S, et al
    Cells to Surgery Quiz: October 2015.
    J Invest Dermatol. 2015;135:e18.
    PubMed     Text format    


    September 2015
  124. FAN Y, Lee S, Wu G, Easton J, et al
    Telomerase Expression by Aberrant Methylation of the TERT Promoter in Melanoma Arising in Giant Congenital Nevi.
    J Invest Dermatol. 2015 Sep 24. doi: 10.1038/jid.2015.
    PubMed     Text format    


  125. NAKAHARA T, Oba J, Shimomura C, Kido-Nakahara M, et al
    Early Tumor-Infiltrating Dendritic Cells Change their Characteristics Drastically in Association with Murine Melanoma Progression.
    J Invest Dermatol. 2015 Sep 15. doi: 10.1038/jid.2015.
    PubMed     Text format     Abstract available


  126. JAYAWARDANA K, Schramm SJ, Tembe V, Mueller S, et al
    Identification, Review and Systematic Cross-Validation of MicroRNA Prognostic Signatures in Metastatic Melanoma.
    J Invest Dermatol. 2015 Sep 9. doi: 10.1038/jid.2015.
    PubMed     Text format     Abstract available


  127. UGUEN A, Talagas M, Marcorelles P, De Braekeleer M, et al
    BRAFV600E and NRASQ61R Homogeneity in Melanoma Tumors.
    J Invest Dermatol. 2015 Sep 3. doi: 10.1038/jid.2015.
    PubMed     Text format    


  128. WEI E, Miteva M
    September 2015 Snapshot Dx Quiz: Linking Science to Patient Care.
    J Invest Dermatol. 2015;135:e32.
    PubMed     Text format    


    August 2015
  129. KEEGAN TH, Swetter SM, Tao L, Sunwoo JB, et al
    Tumor Ulceration does not Fully Explain Sex Disparities in Melanoma Survival among Adolescents and Young Adults.
    J Invest Dermatol. 2015 Aug 19. doi: 10.1038/jid.2015.
    PubMed     Text format    


  130. ROBBINS HA, Clarke CA, Arron ST, Tatalovich Z, et al
    Melanoma Risk and Survival Among Organ Transplant Recipients.
    J Invest Dermatol. 2015 Aug 13. doi: 10.1038/jid.2015.
    PubMed     Text format     Abstract available


  131. HO AW, Tsao H
    Targeted Therapies in Melanoma: Translational Research at Its Finest.
    J Invest Dermatol. 2015;135:1929-33.
    PubMed     Text format    


    July 2015
  132. TANESE K, Hashimoto Y, Berkova Z, Wang Y, et al
    Cell Surface CD74-MIF Interactions Drive Melanoma Survival in Response to Interferon-gamma.
    J Invest Dermatol. 2015 Jul 16. doi: 10.1038/jid.2015.
    PubMed     Text format    


  133. HUTCHENREUTHER J, Vincent KM, Carter DE, Postovit LM, et al
    CCN2 Expression By Tumor Stroma is Required for Melanoma Metastasis.
    J Invest Dermatol. 2015 Jul 13. doi: 10.1038/jid.2015.
    PubMed     Text format     Abstract available


  134. QUAST SA, Steinhorst K, Plotz M, Eberle J, et al
    Sensitization of Melanoma Cells for Death Ligand Trail is Based on Cell Cycle Arrest, Ros Production and Activation of Proapoptotic Bcl-2 Proteins.
    J Invest Dermatol. 2015 Jul 2. doi: 10.1038/jid.2015.
    PubMed     Text format     Abstract available


  135. VAN DEN REEK JM, Kievit W, Gniadecki R, Goeman JJ, et al
    Drug Survival Studies in Dermatology:Principles, Purposes, and Pitfalls.
    J Invest Dermatol. 2015;135:e34.
    PubMed     Text format    


  136. JI Z, Erin Chen Y, Kumar R, Taylor M, et al
    MITF Modulates Therapeutic Resistance through EGFR Signaling.
    J Invest Dermatol. 2015;135:1863-72.
    PubMed     Text format     Abstract available


    June 2015
  137. MAIRHOFER DG, Ortner D, Tripp CH, Schaffenrath S, et al
    Impaired gp100-Specific CD8 T Cell Responses in the Presence of Myeloid-Derived Suppressor Cells in a Spontaneous Mouse Melanoma Model.
    J Invest Dermatol. 2015 Jun 29. doi: 10.1038/jid.2015.
    PubMed     Text format     Abstract available


  138. RIVEIRO-FALKENBACH E, Villanueva CA, Garrido MC, Ruano Y, et al
    Intra- and Inter-tumoral Homogeneity of BRAF Mutations in Melanoma Tumors.
    J Invest Dermatol. 2015 Jun 17. doi: 10.1038/jid.2015.
    PubMed     Text format     Abstract available


  139. TANESE K, Hashimoto Y, Berkova Z, Wang Y, et al
    Cell Surface CD74-MIF Interactions Drive Melanoma Survival in Response to Interferon-gamma.
    J Invest Dermatol. 2015 Jun 3. doi: 10.1038/jid.2015.
    PubMed     Text format     Abstract available


  140. PHADKE M, Gibney GT, Rich CJ, Fedorenko IV, et al
    XL888 Limits Vemurafenib-Induced Proliferative Skin Events by Suppressing Paradoxical MAPK Activation.
    J Invest Dermatol. 2015 Jun 3. doi: 10.1038/jid.2015.
    PubMed     Text format    


  141. HANDOKO HY, Rodero MP, Muller HK, Khosrotehrani K, et al
    Lack of Evidence from a Transgenic Mouse Model that the Activation and Migration of Melanocytes to the Epidermis after Neonatal UVR Enhances Melanoma Development.
    J Invest Dermatol. 2015 Jun 2. doi: 10.1038/jid.2015.
    PubMed     Text format    


  142. WIEDER SY, Serasinghe MN, Sung JC, Choi DC, et al
    Activation of The Mitochondrial Fragmentation Protein Drp1 Correlates with Braf Melanoma.
    J Invest Dermatol. 2015 Jun 1. doi: 10.1038/jid.2015.
    PubMed     Text format    


    May 2015
  143. LESSARD L, Liu M, Marzese DM, Wang H, et al
    The CASC15 Long Intergenic Non-Coding RNA Locus is Involved in Melanoma Progression and Phenotype-Switching.
    J Invest Dermatol. 2015 May 27. doi: 10.1038/jid.2015.
    PubMed     Text format     Abstract available


  144. POSCH C, Cholewa BD, Vujic I, Sanlorenzo M, et al
    Combined Inhibition of MEK and Plk1 has Synergistic Anti-Tumor Activity in NRAS Mutant Melanoma.
    J Invest Dermatol. 2015 May 27. doi: 10.1038/jid.2015.
    PubMed     Text format     Abstract available


    April 2015
  145. KHALIFIAN S, Raimondi G, Brandacher G
    The use of luminex assays to measure cytokines.
    J Invest Dermatol. 2015;135:e31.
    PubMed     Text format    


  146. SIMMONS BJ, Bray FN, Falto-Aizpurua L, Alsaidan M, et al
    Cells to surgery quiz: April 2015.
    J Invest Dermatol. 2015;135:e12.
    PubMed     Text format    


  147. KATIYAR SK
    Hsp90 inhibitor can inhibit UV carcinogenesis.
    J Invest Dermatol. 2015;135:945-7.
    PubMed     Text format     Abstract available


    February 2015
  148. NUGENT JS, Vince R, Raza A
    Topical Acyclothymidine Dinucleosides (aTds) Promote non-UV Mediated Endogenous Defense Mechanisms in Guinea Pig Skin.
    J Invest Dermatol. 2015 Feb 20. doi: 10.1038/jid.2015.
    PubMed     Text format    


    October 2014
  149. SINGH A, Singh A, Sand JM, Bauer SJ, et al
    Topically Applied Hsp90 Inhibitor 17AAG Inhibits Ultraviolet Radiation-Induced Cutaneous Squamous Cell Carcinomas.
    J Invest Dermatol. 2014 Oct 22. doi: 10.1038/jid.2014.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Malignant Melanoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: